Prognostic factors for survival in patients eligible for stem cell transplantation (N = 103 patients)
| Variable . | No. of patients considered . | P (RR, 95% CI) Univariate analyses6-150 . | P (RR, 95% CI) Multivariate analysis6-151 N = 63 patients . |
|---|---|---|---|
| Age | |||
| As a continuous variable | 103 | .06 | — |
| Less than 45 y | 103 | .05 | .13 |
| 1.57 (1.01-2.47) | |||
| Sex | 103 | .29 | — |
| CNS involvement | 103 | .63 | — |
| Myeloid markers6-152 | 100 | .50 | — |
| Anthracycline | 103 | .65 | — |
| Leukocyte count | |||
| As a continuous variable | 103 | .06 | .23 |
| Less than 25 × 109/L | 103 | .35 | — |
| Cytogenetics | |||
| Hyperploidy | 94 | .27 | — |
| Monosomy 7 | 94 | .86 | — |
| Additional abnormalities6-153 | 80 | .28 | — |
| Ph duplication6-153 | 80 | .15 | — |
| NN-AN vs AA | 94 | .36 | — |
| NN vs AN-AA | 94 | .62 | — |
| bcr subtype | 97 | .64 | — |
| No allogeneic donor | 103 | .02 | .02 |
| 1.71 (1.09-2.68) | 2.12 (1.11-40.5) | ||
| Poor response to therapy | |||
| No CR in 1 course | 103 | .08 | .11 |
| BCR-ABL status after 1 course | 45 | .50 | — |
| BCR-ABL status after 2 courses | 63 | .006 | .01 |
| 2.46 (1.26-4.78) | 2.39 (1.21-4.74) |
| Variable . | No. of patients considered . | P (RR, 95% CI) Univariate analyses6-150 . | P (RR, 95% CI) Multivariate analysis6-151 N = 63 patients . |
|---|---|---|---|
| Age | |||
| As a continuous variable | 103 | .06 | — |
| Less than 45 y | 103 | .05 | .13 |
| 1.57 (1.01-2.47) | |||
| Sex | 103 | .29 | — |
| CNS involvement | 103 | .63 | — |
| Myeloid markers6-152 | 100 | .50 | — |
| Anthracycline | 103 | .65 | — |
| Leukocyte count | |||
| As a continuous variable | 103 | .06 | .23 |
| Less than 25 × 109/L | 103 | .35 | — |
| Cytogenetics | |||
| Hyperploidy | 94 | .27 | — |
| Monosomy 7 | 94 | .86 | — |
| Additional abnormalities6-153 | 80 | .28 | — |
| Ph duplication6-153 | 80 | .15 | — |
| NN-AN vs AA | 94 | .36 | — |
| NN vs AN-AA | 94 | .62 | — |
| bcr subtype | 97 | .64 | — |
| No allogeneic donor | 103 | .02 | .02 |
| 1.71 (1.09-2.68) | 2.12 (1.11-40.5) | ||
| Poor response to therapy | |||
| No CR in 1 course | 103 | .08 | .11 |
| BCR-ABL status after 1 course | 45 | .50 | — |
| BCR-ABL status after 2 courses | 63 | .006 | .01 |
| 2.46 (1.26-4.78) | 2.39 (1.21-4.74) |
All survival analyses were performed using the landmark method with a landmark period of 90 days.
RR indicates relative risk of failure; CI, confidence interval; CNS, central nervous system; and Ph, Philadelphia chromosome.
Using the log-rank test for binary variables and univariate Cox models for continuous variables.
Using the Cox model.
Defined as the coexpression of CD34, CD33, and CD13 antigens.
Comparisons were performed in the 80 patients with Philadelphia chromosome.